Mr. Luci is a co-founder of Acurx Pharmaceuticals and has served as its President and Chief Executive Officer and as a director since February 2018. Previously he was President and Chief Executive Officer of Dipexium Pharmaceuticals (Nasdaq: DPRX), an antibiotic-focused pharmaceutical company, from February 2010 until its April 2017 sale to PLx Pharma Inc. (Nasdaq: PLXP) in a merger valued at $69.0 million. From 2009 to 2010 he served on the board of Abeona Therapeutics, where he chaired the Audit and Compensation Committees, and from 2007 to 2009 he was a director and President of MacroChem. Earlier he was Executive Vice President, Chief Financial Officer, General Counsel and Corporate Secretary of Bioenvision, Inc. He began his career as a certified public accountant with Ernst & Whinney (now Ernst & Young) and later practiced corporate law at Paul Hastings LLP. Mr. Luci holds a B.S. in Business Administration (Accounting) from Bucknell University and a J.D. from Albany Law School of Union University, and is a member of the New York State Bar Association.